USA - NYSEARCA:XTNT - US98420P3082 - Common Stock
The current stock price of XTNT is 0.76 USD. In the past month the price increased by 5.17%. In the past year, price increased by 43.22%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| COO | COOPER COS INC/THE | 17.54 | 14.02B | ||
| SOLV | SOLVENTUM CORP | 12.03 | 12.39B | ||
| ALGN | ALIGN TECHNOLOGY INC | 14.14 | 9.91B | ||
| MMSI | MERIT MEDICAL SYSTEMS INC | 23.67 | 5.21B | ||
| LNTH | LANTHEUS HOLDINGS INC | 8.53 | 3.46B | ||
| ICUI | ICU MEDICAL INC | 17.78 | 3.49B | ||
| HAE | HAEMONETICS CORP/MASS | 14.78 | 3.42B | ||
| XRAY | DENTSPLY SIRONA INC | 7.02 | 2.21B | ||
| UFPT | UFP TECHNOLOGIES INC | 27.23 | 1.81B | ||
| NEOG | NEOGEN CORP | 21.27 | 1.39B | ||
| STAA | STAAR SURGICAL CO | N/A | 1.33B | ||
| EMBC | EMBECTA CORP | 4.71 | 804.83M |
Xtant Medical Holdings, Inc. designs, and develops orthobiologics and spinal implant fixation systems to facilitate spinal fusion in complex spine, deformity, and degenerative procedures. The company is headquartered in Belgrade Montana, Montana and currently employs 217 full-time employees. The company went IPO on 2010-06-30. The firm is focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant fixation systems to facilitate spinal fusion in complex spine, deformity, and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. Its biomaterial products include OsteoSponge, OsteoSelect DBM putty, OsteoSelect Plus DBM putty, OsteoWrap, OsteoVive, OsteoFactor, line of 3Demin products, as well as other allografts. The company offers a comprehensive line of products that are used to treat a variety of spinal and sacroiliac conditions, including trauma, degeneration, deformity and tumor. Its key spinal implant product lines include Cervical products, Thoracolumbar products, Sacroiliac Joint products, Interbody products and Interlaminar Stabilization products.
XTANT MEDICAL HOLDINGS INC
664 Cruiser Lane
Belgrade Montana MONTANA 59714 US
CEO: Sean E. Browne
Employees: 225
Phone: 14063880480
Xtant Medical Holdings, Inc. designs, and develops orthobiologics and spinal implant fixation systems to facilitate spinal fusion in complex spine, deformity, and degenerative procedures. The company is headquartered in Belgrade Montana, Montana and currently employs 217 full-time employees. The company went IPO on 2010-06-30. The firm is focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant fixation systems to facilitate spinal fusion in complex spine, deformity, and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. Its biomaterial products include OsteoSponge, OsteoSelect DBM putty, OsteoSelect Plus DBM putty, OsteoWrap, OsteoVive, OsteoFactor, line of 3Demin products, as well as other allografts. The company offers a comprehensive line of products that are used to treat a variety of spinal and sacroiliac conditions, including trauma, degeneration, deformity and tumor. Its key spinal implant product lines include Cervical products, Thoracolumbar products, Sacroiliac Joint products, Interbody products and Interlaminar Stabilization products.
The current stock price of XTNT is 0.76 USD. The price increased by 1.33% in the last trading session.
XTNT does not pay a dividend.
XTNT has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
XTANT MEDICAL HOLDINGS INC (XTNT) has a market capitalization of 106.40M USD. This makes XTNT a Micro Cap stock.
XTANT MEDICAL HOLDINGS INC (XTNT) will report earnings on 2025-11-11, before the market open.
You can find the ownership structure of XTANT MEDICAL HOLDINGS INC (XTNT) on the Ownership tab.
ChartMill assigns a technical rating of 9 / 10 to XTNT. When comparing the yearly performance of all stocks, XTNT is one of the better performing stocks in the market, outperforming 89.27% of all stocks.
ChartMill assigns a fundamental rating of 3 / 10 to XTNT. XTNT may be in some trouble as it scores bad on both profitability and health.
Over the last trailing twelve months XTNT reported a non-GAAP Earnings per Share(EPS) of -0.04. The EPS decreased by -100% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -4.43% | ||
| ROE | -9.44% | ||
| Debt/Equity | 0.46 |
8 analysts have analysed XTNT and the average price target is 1.79 USD. This implies a price increase of 134.87% is expected in the next year compared to the current price of 0.76.
For the next year, analysts expect an EPS growth of 108.5% and a revenue growth 10.6% for XTNT